1. Replimune Stock Crashes to All-Time Low After FDA Rejects Key Melanoma Drug
Replimune Group faces a severe market crisis as its stock price plummets to a record low. The immediate catalyst is a formal rejection from the U.S. Food and Drug Administration for the company's lead melanoma therapy, a devastating blow that has triggered a rapid loss of confidence among investors and analysts. This r...